Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications
ASBMR 2022 Poster Highlights
The following are highlights from the company’s poster presentations of preclinical data exploring spinal fusion and bone cancer indications at ASBMR 2022:
Poster: Improved Spinal Fusion Through Targeted Delivery of Abaloparatide
With more than 400,000 spinal fusions performed in the
U.S.every year, Quince believes there is an opportunity to utilize its bone-targeting platform to improve patient outcomes in spinal fusion with its NOV004 targeted therapeutic.
- Quince developed a bone-targeting compound based on acidic oligopeptides which is designed to stimulate bone growth at spinal fusion sites.
- In preclinical studies, NOV004 concentrated at spinal fusion sites to demonstrate accelerated repair in treated animals which resulted in significantly improved blinded radiographic fusion scores compared to animals treated with the current standard of care, bone morphogenic protein-2 (BMP-2).
- In addition, NOV004’s subcutaneous administration would allow for repeat dosing post operatively compared to current spinal fusion strategies that generally require surgery to apply the drug and only allow for one application.
Poster: Evaluating the Efficacy of an Acidic Oligopeptide-radioisotope Chelator Conjugate to Target and Deliver Radioactive Agents to Bone Cancers
- With five-year survival rates of less than 20% to 30% in patients with breast and prostate cancer related bone metastases, Quince believes there is an opportunity to utilize its bone-targeting platform to develop targeted radiotherapeutics to improve patient outcomes in breast and bone cancer related bone tumor growth.
- Quince developed a radioactive acidic oligopeptide conjugate to target and deliver imaging and therapeutic agents with high tumor-bearing bone specificity.
- In preclinical studies, the company confirmed that its targeting moiety can localize to metastatic tumor sites in both osteolytic and osteoblastic lesions and can selectively deliver both fluorescent dye and radioisotope-chelated agents without obvious offsite localization.
- In addition to demonstrating rapid renal excretion, the radioactive conjugates were retained in the diseased bone even at two weeks post injection.
Statements in this news release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this news release may be identified by the use of words such as “anticipate,” “expect,” “will,” “can,” “may,” “should,” “estimate,” “project,” “potential,” “encouraged,” “positioned,” or other similar words. Examples of forward-looking statements include, among others, the clinical development and strategic development path for NOV004; the timing and success of the company’s clinical trials and related data, including plans and the ability to initiate, conduct and/or complete the Phase 1 clinical studies for NOV004; the potential therapeutic benefits, safety, and efficacy of the company’s bone-targeting platform, product candidate and discovery pipeline. Forward-looking statements are based on Quince Therapeutic’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the company’s Annual Report on Form 10-K filed with the
Quince Therapeutics Contact: